

# Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: www.ajrcps.com https://doi.org/10.36673/AJRCPS.2023.v11.i03.A17



## VALIDATED GRADIENT STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF RELATED SUBSTANCES OF LEVONORGESTREL IN BULK DRUG AND FORMULATION PRODUCTS

## Rohit Dhull\*<sup>1</sup> and Satyavir Singh<sup>1</sup>

<sup>1\*</sup>Department of Chemistry, OPJS University, Churu, Rajasthan, India.

## ABSTRACT

A HPLC method was developed for determination of Related Substances in Levonorgestrel drug substances using Kromasil C18 (250mmx4.6mm, 5µm) column and a mobile phase containing water in gradient combination with acetonitrile (ACN) with flow rate of 1.0mL/min and the chromatogram was monitored using UV Detector at 240nm wavelength. Resolution between Levonorgestrel and its impurities were found more than 1.5 and the stability of test solution and Standard solutions were found upto 24 hours. The LOD and LOQ for Levonorgestrel were observed 0.013% and 0.039%. The analytical method validation of proposed method was performed for various parameters like System suitability, Specificity (interference from Blank and Impurities), Force degradation, LOD and LOQ, Accuracy (Recovery), Linearity, System Precision, Method Precision and Intermediate Precision (Ruggedness) along with Solution stability. The range of method was defined from the data of Precision, Linearity and Accuracy. The Range of method has LOQ to 150% of specification limit. All results for all the validated parameters were found within the acceptance criteria. HPLC method was specific, accurate, precise and suitable for the analysis of Levonorgestrel drug substance and drug products.

## **KEYWORDS**

Levonorgestrel, Kromasil, CAN, Methanol, Stability-indicating, Related substances, ICH guidelines, HPLC and Method Validation.

## Author for Correspondence:

Rohit Dhull, Department of Chemistry, OPJS University, Churu, Rajasthan, India.

Email: dhull.rohit123@gmail.com

Available online: www.uptodateresearchpublication.com

## **INTRODUCTON**

Oral contraceptives are being formulated using an estrogen in a small amount and a synthetic progestin in 5-30 times than the estrogen. Levonorgestrel (or l-norgestrel or d-norgestrel is  $13\beta$ -ethyl- $17\beta$ -hydroxy-18, 19-dinor- $17\alpha$ - pregn-4-en-20-yn-3-one (Figure No.1) is a second-generation synthetic progestogen used as an active ingredient in some hormonal contraceptives, including combined oral

July – September

contraceptive pills including progestogen only pills and emergency contraceptive pills. Levonorgestrel is also used in preparation/manufacturing of intrauterine system, contraceptive implants and hormone replacement therapy.

In Recent years pharmaceutical Preparations Levonorgestrel Containing are available commercially in India as well as other countries. The modern low-dose oral contraceptives require a sensitive. accurate and rapid methods of quantitative determination which is unaffected by the small amount of the estrogen and the large excess of progestogen. HPLC analytical methods have been widely used for analysis in quality assessment of active substance (API's) and their related impurities, because of their sensitivity, repeatability and Specificity. So, method for estimation of Levonorgestrel is developed and validated using HPLC instrument.

Various Regulatory requirements from across the world are now being explicitly defined for identification, qualification and control of impurities in drug substances and drug products.

Regulatory guidelines for validation of analytical methods are particularly defined through the International Council for Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH). As per ICH recommendation that all impurities present in drug substances and drug products at or above 0.1% level, should be identified through appropriate analytical techniques and methods<sup>1-3</sup>. Numerous analytical methods for the determination of Levonorgestrel in bulk drug as well as in formulations have been reported in literature viz. MS/MS<sup>4</sup>, LCMS<sup>5,6</sup>, capillary liquid chromatography and capillary electrochromatography<sup>7</sup>, UV/fluorescence detection<sup>8</sup>, HPTLC<sup>9</sup> and bivariate calibration method and derivative spectrophotometry<sup>10</sup>. Many other stability indicating HPLC<sup>11-13</sup> methods for determination of Levonorgestrel and its related substances (RS) in bulk drug and finished tablets are reported.

Available online: www.uptodateresearchpublication.com

## METHOD DEVELOPMENT Instrument, Chemicals and Reagents Instrumentation

Water alliance 2695 HPLC system with UV and PDA (Photo diode array detector) detector and Kromasil C18 (250mmx4.6mm, 5 $\mu$ m) with a mobile phase containing water in gradient combination with acetonitrile (ACN) at a flow rate of 1.0mL/min. The data were evaluated by Empower2 Software. All the weighing in the experiments was done with Mattler toledo electronic balance capable of measuring with an accuracy of 0.01mg.

## Glassware

All the glassware volumetric used in the study was A-grade.

## Preparation of Diluent

Methanol (diluents) was injected as blank solution.

## **Preparation of Standard Solution**

Weighed accurately about 100mg of Levonorgestrel standard into 100mL clean and dry volumetric flask, dissolve and make up the volume with diluent. (Stock-I).

Pipette out 1.0mL of Stock-I into 100mL volumetric flask and make volume up to the mark with diluent (Stock-II).

Pipette out 5.0mL of Stock-II into 50mL volumetric flask and make volume up to the mark with diluent. (Approx.concentration 1.0ppm).

## Preparation of test solution

An amount of 50mg of active pharmaceutical ingredient (Levonorgestrel) was transferred to a 50mL volumetric flask. Diluent (40mL) was added to it and sonicated for 5 min with intermittent shaking and diluted to volume with the diluent.

## VALIDATIONOF HPLC METHODS System suitability

System suitability is the primary requirement of the any methodology, to ensure that the working conditions are fit for its intended use. The chromatography was performed with Kromasil C18 (250mm length, 4.6mm I.D and 5.0µm particle size) with gradient mentioned in chromatography conditions. A representative chromatogram is shown in Figure No.1, which shows tailing factor July – September 122

for Levonorgestrel is less than 2.0, Theoretical Plates are more than 5000. The response ratio obtained for two 0.1% Levonorgestrel standard injections is between 0.95 to 1.05.

Tailing factor, a parameter that ICH guidelines consider as a factor to be controlled, was within the established limits

## **Specificity and force degradation**

The HPLC chromatograms recorded separately for Blank and Levonorgestrel are displayed in Figure No.2, Figure No.3 and Figure No.4 respectively. The tailing factor for Levonorgestrel peak is 0.8. Peak purity graph shows that there is no interference in Levonorgestrel peak with respect to components present in sample matrix. Thus, the HPLC method presented in this study is specific for Levonorgestrel. To have stability indicating nature of the method, forced degradation studies of Levonorgestrel evaluated and the following degradation behavior is shown, the results were tabulated in Table No.1.

#### **Degradation in acidic conditions**

Levonorgestrel was observed to be degraded to about 7% in acidic conditions, when treated with 2N HCl for 24hours at 60°C. The chromatogram obtained on analyzing the stability sample displayed more than ten peaks for degradation products; degradation product as shown in (Figure No.5).

## **Degradation in basic conditions**

Levonorgestrel was found to be degraded to 10% under basic conditions, when treated with 2N NaOH for 24hours at 60°C. The chromatogram obtained on analyzing the stability sample displayed more five peaks for degradation products; than degradation product as shown in Figure No.6.

## **Degradation under oxidative conditions**

Levonorgestrel was observed to be degraded to about 3% Oxidative conditions, when treated with 30%H2O2 for 24hours at 60°C. The chromatogram obtained on analyzing the stability sample displayed more than five small peaks for degradation products; degradation product as shown in Figure No.7.

## **Degradation in photolytic conditions**

Levonorgestrel was found to be practically stable under the exposed conditions with an overall Available online: www.uptodateresearchpublication.com

illumination of 1.2 million lx h with near-UV energv≥200 Wh/m<sup>2</sup>; the chromatogram is given in Figure No.8 and Figure No.9. This suggests that the drug was stable under photolytic conditions exposed for the period of study.

## **Thermal degradation**

Levonorgestrel was found to be practically stable with dry heat as no degradation was observed when exposed to thermal heat at 105 °C for 24 hours; the chromatogram is given in Figure No.10.

## Degradation under Humidity conditions

Levonorgestrel was found to have a negligible degradation of about 0.20% when treated under 90% RH at 25°C for 168Hours under neutral conditions; the chromatogram is given in Figure No.11.

#### Limit of detection (LOD) and limit of quantification (LOQ)

Limit of Detection (LOD) and Limit of Quantitation (LOQ) level for Levonorgestrel were determined based on Signal to Noise ratio. The Limit of detection (LOD) and Limit of Quantitation (LOQ) Level of Levonorgestrel were derived based on the concentration of LOD and LOQ solutions. The LOD and LOQ were estimated by signal-to-noise ratio of 3:1 and 10:1, respectively, injecting a series of diluted solutions with known concentrations.

## Linearity

Linearity of the method was performed according to ICH Quality guidelines. Suitable solutions with appropriate known concentrations were prepared from stock solution of Levonorgestrel. Stock solution was diluted with the diluent to get solutions containing target concentrations. Linearity of Levonorgestrel was determined over a range of obtained limit of quantification to 150% of specification limit (range was inclusive of concentrations at LOQ, 50, 80, 90,100, 110, 120 and 150%). Calibration curve was obtained by plotting the peak areas of Levonorgestrel versus its corresponding concentration. A graph of peak area vs. concentration ( $\mu$ g/mL) was plotted. Values of the coefficient of correlation, regression and slope of the calibration curve were calculated.

Calibration curves for Levonorgestrel, examined in pure solutions as well as in the laboratory mixture July – September 123

solutions, were found to be linear; correlation coefficients>0.999 in all the cases. Table No.2 enlists the linearity parameters of the calibration curves for Levonorgestrel in laboratory mixture. Statistical treatment of the linearity data of Levonorgestrel shows a linear response between lower levels to highest level. In addition, the analysis of residuals shows values randomly scattered around zero, which fits well within the linear model. The origin of linearity curve was within the lower and the upper limit of 95% that gives high degree of confidence to the value obtained for intercept.

## LOD and LOQ

LOD and LOQ, as a measure of method sensitivity, were provided for degradation products and impurity calculated by means of signal-to-noise ratio. The LOD and LOQ for Levonorgestrel are tabulated in Table No.2. From the results, it can be concluded that the proposed method can quantify small quantity of impurities in Levonorgestrel samples.

## Precision and repeatability

Six solutions containing Levonorgestrel (1000µg/mL) were prepared. Chromatography was performed by HPLC and value of % RSD was calculated for Percentage of highest impurity and total impurities by considering peak area for Levonorgestrel standard and each impurity. In a similar way intermediate precision of the method was also evaluated on different day by another analyst in the same laboratory. The results obtained for repeatability studies and for intermediate precision are presented in Table No.3. Values of % RSD for system precision of Levonorgestrel were 0.0. Method precision has a % RSD 0.0 for repeatability and 0.0 for intermediate precision, which comply with the acceptance criteria.

## Accuracy

Accuracy of method can be inferred with the help of Specificity, Method Precision and Linearity.

## Stability in analytical solution

Sample solution was prepared as directed in the methodology and was stored at refrigerator temperature (2-8°C) and room temperature. The

Available online: www.uptodateresearchpublication.com

stored solutions were injected at initial, 12 hrs and 24 hrs. Results are tabulated in Table No.4 and Table No.5.

The response ratio's W.R.T. initial for Single Max. And total impurities in sample solution at different time intervals are in the range of 95% to 105% when stored at Refrigerated conditions (2-8°C) and room temperature for 24hours, which are well within the acceptance criteria of not more than  $\pm 5.0$ % variation. Based on the obtained data it is concluded that sample solution can be stored and used up to 24hours when stored at Refrigerator temperature (2-8°C) and room temperature.

## Robustness

The robustness of the method is verified for the changing small method by variations of chromatographic conditions by changing the mobile phase flow rate (±0.02mL/min), and changing the temperature from normal  $(\pm 5^{\circ}C)$ . Chromatograms of Levonorgestrel standards and sample solutions were evaluated by applying system Suitability parameters with the robustness changes made. There are no variations observed in system suitability Criteria and results obtained for as such sample. Results are summarized in Table No.6 and Table No.7.

Method robustness checked after deliberate alterations of flow and temperature shows that the changes of the operational parameters do not lead to essential changes of the performance of the chromatographic system. Tailing factor for Levonorgestrel always ranged from 1 to 1.5, Theoretical plates were ranging from 9000-15000 and the %RSD observed for six replicate injections of Standard solution was observed in the range 0.2-1.6. The percent recoveries of Levonorgestrel were good and did not show a significant change when the critical parameters were modified. Considering the results of modifications in the system suitability parameters and the specificity of the method, it would be concluded that the method conditions are robust.

## **RESULTS AND DISCUSSION**

In this study, chromatographic conditions such as the wavelength, mobile phase, column, and column

temperature and flow rate were optimized in order to limit run time while obtaining the best possible peak symmetry and resolution. Levonorgestrel was scanned by a UV detector with variable wavelength to determine its most significant UV wavelength for quantitative purposes. The results showed the best absorption was 240nm for Levonorgestrel.

Too much solvent and matrix interferences were found when the wavelength was less than 220nm. In order to minimize the interferences, a wavelength of 240nm was selected for the detection of Levonorgestrel (Figure No.2). The peak shapes of Levonorgestrel were not sharp and symmetrical when a mobile phase consisted of MeOH-water, and in combination with Gemini C18, Inertsil C18 and Kromasil C18 columns. Peak shapes were significantly improved with mobile phase of ACNwater. Still peak shapes with Gemini C18 and Inertsil C18 column were not significantly good. However, the peak shapes with Kromasil C18 columns were looking good but needed to be optimized by using applying different mobile phase ratios for ACN-Water

Good peak shape and reasonable retention time with measurable resolution were obtained by applying gradient program. Different mobile phase flow rates (0.5, 1.0 and 2.0mL/min) were investigated. The best resolution from all the peaks present and degradants products for Levonorgestrel were obtained when flow rate was 1.0mL/min.

Based on the development study a simple mobile phase filtered and degassed water is selected as mobile phase-A and Acetonitrile as counterpart viz. mobile phase-B. The chromatographic elution is performed in Kromasil  $C_{18}$  columns. The separations were achieved by modifying different gradients programs. The finalized method has a gradient composition of Time(min)/% Mobile Phase-B (0 min/40%, 8min/45%, 35min/45%, 45 min/40% and 55 min/40%) with Kromasil C<sub>18</sub> (250mmx4.6mm, 5µm) column, 25°C as column oven temperature, injection volume 20µL,column temperature 25°C and eluent is monitored at 240nm.

	Chemical structure of n-nitrosodimethylamine and metformin hydrochloride						
	<b>Levonorgestrel</b> <i>Chemical formula:</i> C <sub>21</sub> H <sub>28</sub> O <sub>2</sub>						
	Molecular weight: 312	2.453	0	T A T A			
	The following reagents and chemicals were used during the evaluation studies						
S.No	Chemicals	Specific	ations	Manufactures			
1	Acetonitrile	HPLC –	Grade	HPLC grade Rankem ltd			
2	Methanol	HPLC –	Grade	HPLC grade Rankem ltd			
3	Milli Q Water	Double D	Distilled	Milli-Q RO system			
4	Hydrochloric acid	AR – C	Grade	Merck			
5	Sodium hydroxide	AR- G	rade	Rankem			
6	Hydrogen Peroxide	AR- G	rade	Rankem			
7	Levonorgestrel	Active Pharmaceu	utical Ingredient	Surya Pharmaceutical India			
	(	Chromatographic C	Conditions for l	LC			
S.No	Param	eters		Description			
1	Mobile P	hase A		Milli-Q-water			
2	Mobile P	hase B		Acetonitrile			
3	3 Flow rate			1.0ml/min			
4	4 Column Temp.			25°C			
5	5 Sample temperature			25°C			
6	Injection	volume		20µl			
7	Run t	ime		55 minutes			

Available online: www.uptodateresearchpublication.com

		Gradient	Program for LC					
S.No	Time (Minutes)	Mobile	Mobile phase A (% v/v)			Mobile phase B (% v/v)		
1	0.00		60		40			
2	8.0		55		4:	5		
3	35.0		55		4:	5		
4	45		60		40	0		
5	55		60		40	0		
r	Table No.1: Specificity part-E	<b>B</b> Stress studie	s representing d	egradatio	on in various p	arameters		
S.No	Solid State Stress condition	%Total Impurities	% Degradation	Purity Angle	Purity Threshold	Peak Purity results		
1	Control Sample	0.05		0.596	1.982	Pass		
2	Thermal Degradation (105°C) for 24Hours	0.05	0.00	0.650	1.802	Pass		
3	UV Degradation 200Wh/m <sup>2</sup>	0.05	0.00	0.709	1.912	Pass		
4	Visible Degradation 1.2millon Lux hours	0.05	0.00	0.632	1.703	Pass		
5	Humidity Degradation (90% RH at 25°C168Hours)	0.05	0.00	0.637	1.606	Pass		
		Liquid Stat	e Stress condition	n				
6	Control Sample	0.05		0.689	1.784	Pass		
7	Stressed with 2N HCl 24hrs at 60° C	7.32	7.27	0.024	0.433	Pass		
8	Stressed with 2N NaOH 24hrs at 60° C	9.86	9.81	0.096	0.358	Pass		
9	Stressed with 30% H2O2	3.02	2 97	0.202	0.857	Pass		

Table No.2: LOD and LOQ results for Levonorgestrel

2.97

3.02

		LOD			LOQ		
S.No	Compound	Concentration (mg/ml)	Concentration W.R.T. Sample	s/n	Concentration (mg/ml)	Concentration W.R.T. Sample	s/n
1	Levonorgestrel	0.14	0.015	3.78	0.44	0.044	12.62
		1	••• ••	•		e (· · ·	C

 Table No.3: Intra-day and intermediate precision of Levonorgestrel (% RSD of n=6 injections of test

concentration)

	Sampla	Method Precision		Intermediate Precision		
S.No	Sample Preparations	Single Maximum impurity (%w/w)	Total impurities (%w/w)	Single Maximum impurity (%w/w)	Total impurities (%w/w)	
1	Preparation-1	0.05	0.07	0.05	0.07	
2	Preparation-2	0.05	0.07	0.05	0.07	
3	Preparation-3	0.05	0.07	0.05	0.07	
4	Preparation-4	0.05	0.07	0.05	0.07	
5	Preparation-5	0.05	0.07	0.05	0.07	
6	Preparation-6	0.05	0.07	0.05	0.07	

Available online: www.uptodateresearchpublication.com

24hrs at 60°C

9

July - September

0.202

0.857

Pass

Rohit Dhull and Satyavir Singh. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 11(3), 2023, 121-132.

7	Average	0.05	0.07	0.05	0.07
8	% RSD	0.00	0.00	0.00	0.00
		Comparis	son Table (Method	VS Intermediate Prec	cision)
	Sample	Single Maximum in	mpurity (%w/w)	Total impurit	ies (%w/w)
P	Preparations	Method Precision	Intermediate Precision	Method Precision	Intermediate Precision
9	Preparation-1	0.05	0.05	0.07	0.07
10	Preparation-2	0.05	0.05	0.07	0.07
11	Preparation-3	0.05	0.05	0.07	0.07
12	Preparation-4	0.05	0.05	0.07	0.07
13	Preparation-5	0.05	0.05	0.07	0.07
14	Preparation-6	0.05	0.05	0.07	0.07
15	Average	0.05	0.05	0.07	0.07
16	% RSD	0.00	0.00	0.00	0.00
17	Overall %RSD	0.00	)	0.0	)

## Table No.4: Results of single maximum impurity in sample solution

	Time (hrs)	Single Max. Impurity				
S.No		At Refrigerated Conditions (2-8°C)		Room temperature		
		<b>Injection</b> Area	<b>Response Ratio</b>	Injection Area	<b>Response Ratio</b>	
1	Initial	460172	-	460172	-	
2	12 hours	471164	102.4	470856	102.3	
3	24 hours	469752	102.0	471462	102.5	

#### Table No.5: Results for total impurities in sample solution

	Time (hrs)	Single Max. Impurity				
S.No		At Refrigerated Conditions (2-8°C)		Room temperature		
		<b>Injection</b> Area	<b>Response Ratio</b>	Injection Area	<b>Response Ratio</b>	
1	Initial	701822	-	701822	-	
2	12 hours	702984	100.2	696789	99.3	
3	24 hours	699896	99.7	699426	99.7	

#### Table No.6: Results for single highest impurity

		% of Single Highest impurity		
S.No	Conditions	% of Single	% Difference W.R.T	
		<b>Highest impurity</b>	original condition	
1	Original (Method Precision -Sample preparation-1)	0.05		
2	Flow rate variation –Low Flow (0.8mL/min)	0.05	0.00	
3	Flow rate variation-High Flow (1.2mL/min)	0.05	0.00	
4	Column oven Temperature Variation 20°C	0.05	0.00	
5	Column oven Temperature Variation 30°C	0.05	0.00	

Rohit Dhull and Satyavir Singh. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 11(3), 2023, 121-132.

		% Sum of All impurities		
S.No	Conditions	% Sum of All impurities	% Difference W.R.T original condition	
1	Original (Method Precision -Sample preparation-1)	0.07		
2	Flow rate variation –Low Flow (0.8mL/min)	0.07	0.00	
3	Flow rate variation-High Flow (1.2mL/min)	0.07	0.00	
4	Column oven Temperature Variation 20°C	0.07	0.00	
5	Column oven Temperature Variation 30°C	0.07	0.00	







Figure No.1: Chromatogram for Standard (1ppm)



rigure 10.3. Embinatogram and runny plot of Sample

Available online: www.uptodateresearchpublication.com July – September

Rohit Dhull and Satyavir Singh. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 11(3), 2023, 121-132.




Figure No.7: Chromatograms of peroxide stressed samples treated with 30% H<sub>2</sub>O<sub>2</sub> refluxed at 60°C for 24 hours

Available online: www.uptodateresearchpublication.com July – September 129




Figure No.11: Chromatogram for humidity degradation

Available online: www.uptodateresearchpublication.com July – September

130




Figure No.12: Linearity curve

## CONCLUSION

The proposed HPLC method for estimation of related substances for Levonorgestrel is validated in drug substance as per ICH guidelines. The method is found to be specific and suitable for the analysis. This method can produce Specific, Precise and Accurate results during regular analysis of product. Method is specific to determine the related substances as no interference is observed from Blank and unknown compounds at the retention time of Levonorgestrel and known impurities. The range of analytical method is suitable to determine the Organic impurities in the range of LOQ to 150% of specification level. Hence, the proposed method is validated and can produce Specific, Precise and Accurate during analysis.

## ACKNOWLEDGEMENT

The authors wish to express their sincere gratitude to Department of Chemistry, OPJS University, Churu, Rajasthan, India for providing necessary facilities to carry out this research work.

## **CONFLICT OF INTEREST**

We declare that we have no conflict of Interest.

## BIBLIOGRAPHY

- 1. ICH. Stability testing of new drug substances and products, *Q1A (R2)*, 2003.
- 2. ICH. Impurities in new drug substances, *Q3A (R1)*, 2006.
- 3. ICH. Impurities in new drug products, *Q3B* (*R1*), 2006.

Available online: www.uptodateresearchpublication.com

- 4. Kumar *et al.* A Rapid and Sensitive UPLC– ESI-MS/MS method for determination of levonorgestrel by chemical derivatization in human plasma and its application to pharmacokinetic study, *J Anal Bioanal Techniques*, S6(6), 2014, 1-8.
- 5. Bhargavi P. Quantitative bioanalysis of levonorgestrel in human plasma using LC-MS/MS, *Int. J. Inst. Pharm. Life Sci*, 1(2), 2011, 39-48.
- 6. Theron H. Selective and sensitive LC-MS/MS method for the determination of levonorgestrel in human plasma, *J. Chromatogr. B*, 813(1-2), 2004, 331-336.
- 7. Chankvetadze B. Comparative study on the application of capillary liquid chromatography and capillary electrochromatography for investigation of enantiomeric purity of the contraceptive drug Levonorgestrel, *J. Pharm. Biomed. Anal*, 30(6), 2003, 1897-1906.
- 8. Arsova-Sarafinovska Z. Determination of ethinyl estradiol and levonorgestrel in oral contraceptives with HPLC methods with UV detection and UV/fluorescence detection, *Maced Pharm. Bulletin,* 52(1), 2006, 9-16.
- 9. Shamsipur M. Stability-indicating highperformance thin-layer chromatographic and high-performance liquid chromatographic determination of levonorgestrel and ethinyl estradiol in bulk drug and in low-dosage oral contraceptives, *Anal. Chim. Acta*, 572(2), 2006, 237-442.

July – September

- 10. Mohammadpour K. Application of bivariate calibration method and derivative spectrophotometry to simultaneous quantitative resolution of ethinyl estradiol and levonorgestrel in pharmaceutical formulations, *J. Appl. Chem. Res,* 3(10), 2009, 17-24.
- 11. Tao Tang, Pingliang Li, Laixin Luo, Dazhao Jiangiang Li. Development Shi. and validation of HPLC method for а determination of levonorgestrel and quinestrol in rat plasma, Biomed. Chromatogr, 24(7), 2010, 706-710.
- 12. Tejal Rathod and Anandkumari D. Captain et al. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of ethinyl estradiol and levonorgestrel, *International Journal of Pharmaceutical Research and Analysis*, 4(3), 2014, 178-185.
- 13. Tang T. Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma, *Biomed. Chromatogr*, 24(7), 2010, 706-710.
- 14. Siddiqui M R. *et al.* Analytical techniques in pharmaceutical analysis: A review, *Arabian Journal of Chemistry*, 10(1), 2013, S1409-S1421.
- 15. Development and validation of stability indicating RP-HPLC and UV spectrophotometric methods for estimation of levonorgestrel in pharmaceutical formulation.
- 16. Phani R S Ch *et al.* Scientific approach for RP-HPLC method development: Complete review, *IJSID*, 2(6), 2012, 218-228.
- 17. Vibha Gupta *et al.* Development and validation of HPLC method a review, *Int. Res J Pharm. App Sci,* 2(4), 2012, 17-25.

- 18. Ravindra A, Hima P, Narayana Swamy K, Vinod Kumar K. Validated UV spectrophotometric method for the simultaneous estimation of levonorgestrel and ethinylestradiol in oral dosage form by absorption correction method, *Journal of Scientific and Innovative Research*, 2(3), 2013, 642-650.
- 19. *IJARPB*, 4(1), 2014, 1-10.
- 20. Azim Md. Sabir *et al.* HPLC method development and validation: A review, *Int. Res. J. Pharm*, 4(4), 2013, 39-46.
- 21. http://www.ich.org/fileadmin/Public\_Web\_S ite/ICH\_Products/Guidelines/Quality/Q2\_R 1/Step4/Q2\_R1\_\_Guideline.pdf.
- 22. https://hmc.usp.org/sites/default/files/docum ents/HMC/GCs-Pdfs/c621.pdf.
- 23. https://hmc.usp.org/sites/default/files/docum ents/HMC/GCs-Pdfs/c1225.pdf.
- 24. United States Pharmacopeia 32, Verification of Compendial Methods.
- 25. Hari Darshan Singh, Rahul Kumar, Harendra Singh, Rahul Dev, Anil Kumar. Method development and validation for quantification of N, N-dimethylformamide in telmisartan drugs substance by reverse using detector. phase HPLC UV International Journal of All Research Scientific Education and Methods (IJARESM), 10(7), 2022, 581-590.
- 26. Rahul Kumar and Shyam Sunder Shrivastava. Development of chromatographic method for determination of release of enzyme from enteric coated tablets by HPLC, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences*, 11(2), 2023, 54-59.

**Please cite this article in press as:** Rohit Dhull and Satyavir Singh. Validated gradient stability indicating hplc method for the determination of related substances of levonorgestrel in bulk drug and formulation products, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences*, 11(3), 2023, 121-132.

Available online: www.uptodateresearchpublication.com July – September